Program Overview
GRIN Therapeutics has its roots in working with patients, caregivers, and families of people living with developmental and epileptic encephalopathies. Our connections with those living with these conditions continues to inform the design and structure of our clinical development programs. We believe in putting people at the center of everything we do.
Our Clinical Trial Program
GRIN Therapeutics is currently developing radiprodil, an investigational negative allosteric modulator of the GluN2B (NR2B) subunit of the NMDA receptor, in neurodevelopmental disorders including GRIN-related neurodevelopmental disorder, Tuberous Sclerosis Complex (TSC), and Focal Cortical Dysplasia Type II (FCDII).
For more information on our currently enrolling studies:
- For GRIN-NDD:
- For TSC and FCDII: